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Summary 
The/3-adrenergic receptor, transduction processes and catalytic activity of the adenylate cyclase enzyme 
complex have been investigated in rabbit heart at different stages of biological maturation. The binding of 
[3H]-dihydroalprenolol to a washed membrane preparation isolated from rabbit ventricular muscle was used 
to characterize fl-adrenergic receptors. Significant age-related differences were noted in B-receptor affinity 
(Kd) and density (RD) of neonatal and adult animals; the adult K d was 3.7-fold greater and the RD 2-fold 
higher than the neonates. No significant differences in these parameters were detected among the 27-day old 
fetus and the 1- and 7-day old neonates. Age-dependent differences in agonist isoproterenol affinity for the 
receptor were not observed in contrast to the significant changes in antagonist (DHA) affinity. 
Age-related changes in receptor affinity were also quantitated by determining the inhibitory potency of 
alprenolol on isoproterenol stimulated adenylate cyclase enzyme activity. A decreased affinity of the 
/3-adrenergic receptor for alprenolol in the adult heart was indicated by a 3.7-fold greater K i for the adult than 
the 1-day old neonate. Ontogenic variations in the coupling efficiency between the receptor and catalytic 
components of the adenylate cyclase complex were also evaluated. The K d of the fl-adrenergic receptor for 
isoproterenol and the EC50 for adenylate cyclase stimulation were determined under similar conditions. The 
corresponding coupling index (Kd/EC50) was found to be 2.4-fold greater in the 1-day old neonate than 
adult, suggesting that for a given percentage increase in adenylate cyclase activity, a lower percentage of 
/3-adrenergic receptor sites need be occupied in the neonate. These data extend previous studies (29) and 
indicate all components of the rabbit heart adenylate cyclase enzyme complex (i.e., the/3-adrenergic receptor, 
the GTP-dependent transduction event, and the catalytic subunit) exhibit significant developmental changes. 
Introduction 
The major functional components of the adenyl- 
ate cyclase (AC) enzyme complex consist of a recep- 
tor that selectively recognizes and binds specific 
hormones, a catalytic subunit that promotes forma- 
tion of adenosine Y:5'-monophosphate (cAMP) 
from ATP and a transducer or coupling system that 
determines the efficiency with which an occupied 
receptor stimulates or inhibits the catalytic activity 
(26). Numerous studies have described the effects of 
biological maturation on AC alone (15); however, 
few have examined the functional integration of the 
components during development (29). 
In the present investigation, several/3-adrenergic 
receptor-related parameters (i.e., receptor-ligand 
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binding, coupling efficiency and AC activity) have 
been concurrently evaluated in the 27-day old fetal, 
1- and 7-day old neonatal and adult rabbit hearts. 
These data suggest that changes in /3-adrenergic 
receptor affinity and density as well as coupling 
efficiency occur in the rabbit heart during the post- 
natal period. 
Methods 
Washed particulate membrane (WPM) 
preparations 
New Zealand White Rabbits were obtained from 
the Oak Crest Rabbitry in Hanover, Minnesota. 
Average weights (mean _+_ S.D.) were: 35 ± 12 g 
(27-day old fetus), 59 + 13 g (1-day old), 113 ± 29 g 
(7-day old), and 2,8 -+- 0.4 kg (adult). Animals were 
sacrificed by a stunning blow to the head, the hearts 
excised within 2-3 minutes and placed in ice-cold 
buffer A (10mM Tris-HC1, pH7.4 at 4 ° C  with 
2 mM dithiothreitol). The number of hearts pre- 
pared simultaneously varied according to the age of 
the animal. In general, the ensuing schedule was 
used: 27-day old fetus (9-I0 hearts), 1- and 7-day 
old neonate (4-5 hearts) and adult (1 heart). The 
pooled hearts were always obtained from litter- 
mates. Atria and vessels were removed and the 
resulting ventricular muscle minced with a scissors. 
All tissue preparation was carried out at 4 ° C. 
The ventricular tissue yields were approximately 
1.0 gram (27-day old fetus), 1.0-1.5 grams (1-day 
old), 1.5-2.0grams (7-day old), and 2-4grams 
(adult). The tissuemince was suspended in buffer A 
(10 volumes/wt) and homogenized at 4 ° C  in a 
Waring blender for 6-16 seconds duration, depend- 
ing upon the amount of cardiac tissue used. Further 
homogenization was carried out in a Tekmar SDT 
tissuemizer using a 10-sec duration at setting 70 and 
a 2-sec duration at setting 100. The tissue suspen- 
sion was then filtered through a 250 # nylon mesh 
and the filtrate collected. 
Washed particulate membranes (WPM) were 
prepared by subjecting this filtrate to the following 
series of low speed centrifugations using a Sorvall 
SS-34:600 gfor  15 rain,, 400 gfor  10 min, 200 gfor  
10 min, and 200 g for 10 min. The pellet was re- 
tained after each centrifugation and resuspended in 
5 volumes of buffer A with 6 strokes of a motor- 
driven Teflon pestle homogenizer. The pellet from 
the 600 g centrifugation was gently washed with 
buffer A to remove the fluffy lipid layer which was 
discarded. Following the final 200 g centrifugation 
the pellet was resuspended in 10 volumes of buffer 
B (buffer A + 0.25 M sucrose) and centrifuged at 
30 000 g for 15 rain. The resulting pellet was washed 
three times with 5 ml of buffer C(5 mM MgC12 and 
50 mM Tris-HC1 pH 7.4, at 37 ° C) and resuspended 
with a motor-driven teflon pestle homogenizer in 
an equal volume of buffer C to yield approximately 
2 mg protein/ml. This suspension was aliquoted 
into 0.5 2.0 ml volumes, frozen immediately in dry 
ice-acetone and stored at -70 ° C. Membranes could 
be stored in this manner for up to 9 months without 
loss of receptor binding or adenylate cyclase activ- 
ity; however, they were typically used within 
3 months. This preparation was similar to that des- 
cribed by Snyder and Drummond (31), the major 
alteration being the elimination of the KC1 extrac- 
tion of contractile proteins. Proteins were deter- 
mined by the Lowry method (19) using a standard 
comprised of bovine serum albumin. 
Adenylate cyclase assay 
The enzymatic reaction was carried out in an 
incubation volume of 0.5 ml that contained 50 mM 
Tris-HC1 (pH 7.4), 1.8 mM ATP, 2.5 #g R020 
(phosphodiesterase inhibitor), 0.25 mM EGTA, 
2 mM mercaptoethanol, 1.9 units pyruvate kinase 
(PK), 5 mM phosphoenolpyruvate (PEP), 5.5 mM 
KC1, 1.0 #M guanyl-5'-yl imidodiphosphate 
(Gpp(NH)p, a GTP analog), 2.5 mM MgCI~ and 
approximately 0.! mg membrane protein. Reac- 
tions were initiated by addition of membrane sus- 
pensions to prewarmed tubes that were maintained 
in an oscillating water bath set at 37 °C. Incuba- 
tions were carried out for 8-min periods during 
which time enzyme velocities were shown to be 
linear. All reactions were terminated by inserting 
the test tube in a boiling water bath for 3 min. 
Samples were stored at 4 °C until assayed for 
cAMP by a competition binding procedure (4, 29). 
~-Adrenergic receptor binding assay 
The ligand binding reaction was performed at 
37 °C in an oscillating water bath. All reactions 
were carried out in triplicate. This process was in- 
itiated by adding 0.08 ml of membrane preparation 
(0.1 0.3 mg protein) to a reaction mixture (0.2 ml 
final volume) contained in polystyrene tubes. The 
incubation media were similar to those used in the 
adenylate cyclase enzyme assay and included: 
50 mM Tris-HC1 (pH 7.4), 1.8 mM ATP, 2.5 #g 
R020, 2.5 mM EGTA, 2 m M  mercaptoethanol, 
5 m M  PEP, 1.9 units PK, 5.5raM KCI, l m M  
MgC12 and [3H]-DHA. Non-specific binding was 
determined by addition of 10 #M propranolol to 
duplicate tubes. The reaction was terminated after 
13 min by rapid addition of 3 ml ice-cold buffer C. 
The entire mixture was then filtered over a Gelman 
type AE glass fiber filter paper held in a millipore 
filtration manifold and washed with 12 ml of cold 
buffer C. A continuous vacuum sufficient to pro- 
duce a flow rate of 1 ml/sec was applied during the 
entire filtration which was completed within 20 sec. 
The filters were air dried and placed in a vial con- 
taining 10 ml of scintillation cocktail (toluene with 
0.04% 2a70 omniflour). Samples were counted in a 
scintillation spectrometer at an efficiency of 45% 
for 10 min. 
Statistical analysis 
Tests of equality between the means of groups 
were performed using the Student's t-test. When 
more than two groups were compared, interactions 
were determined by the one factor analysis of var- 
iance (ANOVA) or two factor ANOVA with re- 
peated measures; if interactions were found, Dun- 
can's least square test was used to determine which 
group means differed significantly. Least squares 
linear regression analysis was employed in Scat- 
chard and Schild plot analyses. 
Materials 
[3H]-cyclic AMP (40-60Ci/mmole) and [3H]- 
DHA (32-49 Ci/nmole) were purchased from the 
New England Nuclear Co. and (d-, 1-) Gpp(NH)p 
from ICN Pharmaceuticals. 2-Mercaptoethanol 
was obtained from Eastman Organic, 2a70 from 
Research Products International and Norit SG Ex- 
tra charcoal from the Baker Company. ATP, phos- 
phoenolpyruvate, pyruvate kinase, DTT, BSA, d,1- 
and l-isoproterenol, 1-phenylephrine and d- and 
1-norepinephrine were purchased from Sigma. 
Propranolol and 1-alprenolol were generously pro- 
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vided by the Ayerst Pharmaceutical Co. and RO- 
20-1724 was a gift from H. Sheppard (Hoffman- 
LaRoche). 
Results 
[3H]-DH/t binding to washed particulate mem- 
branes (WPM): characteristics of the ligand-re- 
ceptor interaction 
The binding properties of [3H]-DHA to WPM 
was initially studied in preparations derived from 
adult rabbit hearts. The specific binding of [3H]- 
DHA to receptor sites was saturated with increas- 
ing ligand concentration and Scatchard analyses of 
these data (Fig. 1) demonstrated a K d of 11.3 nM 
and a RD of 176 fmol /mg protein. Specific binding 
at 10 nM [3H]-DHA was 70% of the total counts 
bound. About  half of the non-specific binding was 
present on- the filter discs. 
Stereospecificity of the ligand-receptor interac- 
tion was determined by comparing the displace- 
ment of bound [3H]-DHA in the presence and ab- 
sence of 1- and d-isomers of several B-adrenergic 
agonists (Fig. 2). The compounds employed in 
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Fig. 1. Specific binding o f p H ] - D H A  to myocardial  membranes 
(WPM) from adult rabbits. WPM (A, o) fractions were incubat- 
ed as described in Methods. Specific binding, that displaceable 
by 10 5 M dl-propranolol has been plotted as a function of 
[3H]-DHA concentratioxL The insert is a Scatchard plot (27) of 
the data from which the K d and RD were estimated from the 
slopes and abscissa intercepts, respectively. Results were aver- 
aged from 2 experiments on separate membrane preparations. 
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Fig. 2. Effect of/3-adrenergic agonists on [3H]-DHA binding in adult rabbit myocardial membranes. WP M from three adult rabbits were 
incubated as described in Methods with 10 nM [3H]-DHA and various concentrations of the following /3-adrenergic agonists: 
l-isoproterenol (©), d-isoproterenol (e), l-norepinephrine (A), d-norepinephrine (A), l-phenylephrine (D). Binding was expressed as the 
percentage of total [JH]-DHA bound and was plotted against agonist concentration. Specific binding averaged 75% of the total counts 
bound. Data expressed as mean _ SEM (n = 3). K d values were calculated from these data using the equation Kd = I(250/1 ÷ (S)/K m 
where I(250 represents the concentration of drug inhibiting specific binding by 50%, S equals the concentration of[3H]-DHA and K m the 
K d of[3H]-DH A determined from Scatchard analysis. The resulting K d (#M) values were: 0.3 (1-isoproterenol), 8.5 (d-isoproterenol), 4.9 
(l-norepinephrine), 550 (d-norepinephrine), 55 (1-phenylephrine). 
tively and the following order of potency: l-iso- 
proterenol > 1-norepinephrine > 1-phenylephrine. 
The relative potency of the 1- and d-stereoisomers 
1/d in this regard was 11 for norepinephrine, and 
28 for isoproterenol. 
Kinetic analyses of specific [3H]-DHA binding to 
WPM demonstrated that equilibrium was achieved 
within 2 min and remained stable for 15 rain. When 
10 #M d-, 1-propranolol was added to the reaction 
mixture, after equilibrium had been established, 
about 90% of the specifically bound [3H]-DHA was 
dissociated within 3 min (data not shown). 
Effect o f  biological maturation on binding of[3 H] - 
D H A  to washed particulate membranes 
The relationship between [3H]-DHA concentra- 
tion and specific binding of WPM derived from 
27-day old fetal, 1- and 7-day old neonatal and 
adult rabbits was analyzed (Fig. 3). Specific binding 
in these experiments was approximately 70% of the 
total binding at I0 nM [3H]-DHA. Saturation was 
more clearly observable in WPM isolated from the 
27-day old fetus and adult than in the 1- or 7-day 
old neonate over a broad concentration is ligand 
used (1-50 nM, [3H]-DHA). Scatchard analyses 
(27) of these data were linear for the adult and 
27-day old fetus, suggesting that a single class of 
binding sites dominated in these preparations. In 
contrast, the 1- and 7-day old neonates generated 
curvilinear plots, reflecting a lack of saturation be- 
tween 30-50 nM [3H]-DHA (Fig. 4). 
The K d and RD values obtained for the high 
affinity binding sites are summarized in Table 1. 
There were no significant differences between the 
27-day old fetus and 1-or 7-day old neonate with 
respect to either parameter. However, the adult K d 
was 3- to 4-fold greater and the RD approximately 
2-fold higher than any of the younger age groups. 
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Fig. 3. Specific binding of [3H]-DHA to rabbit myocardial  membranes  as a function of biological maturat ion.  WPM from 27-day old 
fetus (13), l -day old neonatal (m), l-week old neonatal  (©), and adult (A) were incubated with various concentrations of [3H]-DHA and 
specific binding determined as described in the Methods section. Each point constitutes an average of experiments performed on 
separate membrane  preparations: 27-day old fetus (n = 4-6), l -day old neonatal  (n = 5), 1-week old neonatal  (n = 4 10) and adult  (n = 
4 8). 
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Fig. 4. Scatchard analysis of [3 H]-DHA specific binding to myocardial membranes  as a function of biological maturation.  Data analyzed 
were obtained from the experiments described in Fig. 3 and contrast the 27-day old fetus (13) and 1-day old neonatal (m) in panel A and 
the 7-day old neonatal  (©) with adult  (A) in panel B. The correlation value (r) for the leas t square regression analysis were as follows: (13) = 
0.986, (m) = 0.940, (o) = 0.980, ( ' )  = 0.920. The (+) data for the 1- and 7-day old neonatals were omitted from the analysis since they 
appeared to comprise another  binding component  of low affinity. 
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Table 1. Scatchard analysis of individual membrane prepara- 
tions. 
r K d (nM) Bmax(fmol/mg ) 
Adult -0.958 8.69 188 
0.849 9,57 143 
-0.964 9.75 137 
0.916 23.20 227 
0.972 22.69 276 
0.966 15.10 218 
-0.989 8.95 160 
0.979 7.75 137 
Ave ± SEM 13.2 +_ 2.3 186 -r- 18.0 
7-day old 
neonatal 
0.931 5.70 154 
-0.923 4.69 152 
0.933 4.02 96 
-0.855 2.61 115 
-0.824 2.60 68 
0.940 2.63 77 
Ave_+ SEM a3.8 ± 0.5 a l l l  ± 12.7 
l-day old 
neonatal 
0.850 2.85 88 
0.826 5.34 68 
0.827 2.68 50 
0.866 3.41 99 
0.945 4.30 124 
Ave ± SEM a3.7 4- 0.5 a86± 13 
27-day old 
fetus 
0.976 2.24 74 
0.841 4.70 131 
0.921 2.54 70 
0.940 2.17 80 
0.915 3.84 104 
0.924 3.44 122 
Ave ± SEM a3.2 ± 0.4 ac 
a Less than adult, p < 0.001. 
Data were obtained by the method indicated in Fig. 4 except that 
individual rather than pooled data have been presented. 
Inhibition of  WPM adenylate cyclase activity by 
l-alprenolol 
The K i of 1-alprenolol was determined by deter- 
mining its potency as an inhibitor of isoproterenol- 
stimulated adenylate cyclase activity in WPM pre- 
pared from adult and !-day old rabbits. Increasing 
concentrations of 1-alprenolol produced parallel 
shifts in the 1-isoproterenol dose-response curve 
(data not shown). The competitive nature of this 
inhibition was confirmed by slope values of unity 
(range 0.991 to 1.074) and the ability of high ±so- 
proterenol concentrations to overcome alprenolol 
inhibition. Schild analyses (28) of these data indi- 
cated that the average K i for the adult (3.50 ± 
0.17 nM) was 3.7-fold greater (p < 0.05) than of the 
l-day old neonate (1.01 ___ 0.22 nM) (Fig. 5). These 
observations suggest that the affinity of the recep- 
tors in the neonatal WPM have a greater affinity for 
fl-adrenergic antagonists than the adult. 
Relationship between receptor occupation and ad- 
enylate cyclase activation by l-isoproterenol: cou- 
pling efficiency of  reaction 
The IC50 of isoproterenol for [3H]-DHA occu- 
pied receptor sites was used to determine the K d of 
the agonist in WPM prepared from 1-day old and 
adult hearts. The average K d of the neonate (0.32 
~M) did not differ significantly from that of the 
adult (0.30 #M). The average ECs0 for isoprotere- 
nol-induced stimulation of adenylate cyclase was 
0.047 #M in the 1-day old and 0.108/~M in the 
adult (p ~ 0.001). In these experiments the GTP 
analog, Gpp(NH)p, was always present in these 
experiments at a concentration of 1.0 #M. It failed 
to elicit any shift in the ECs0 of isoproterenol, al- 
though the enzymatic activity of the preparation 
was increased two-fold in the presence of this com- 
pound. The coupling efficiency index (Kd/EC50 ) 
determined from these data was found to be greater 
in the 1 -day old neonate (0.34/~M/0.047 #M = 6.8 ) 
than in adult (0.30 #M/0.108 #M --2.8 ). 
Discussion 
The binding of [3H]-DHA to membrane frac- 
tions prepared from rabbit heart membranes has 
been shown to fulfill accepted criteria for the identi- 
fication and characterization of B-adrenergic recep- 
tors. The lack of a well-defined saturation pattern 
for [3H]-DHA specific binding was noted in WPM 
prepared from 1- and 7-day old neonatal myocar- 
dium. The resulting concave-upward Scatchard 
plot may indicate the existence of two classes of 
binding sites, a two step reaction process, or nega- 
tive cooperativity among sites. Quantitation and 
interpretation of the K d was, therefore, made less 
precise by the non-linearity of these plots. Prece- 
dents for these observations have been previously 








-9 -8  -7 - 6  
Log [{-ALPRENOLOL], M 
179 
Fig. 5. Schild anal~(sis of 1-alprenolol inhibition of 1-isoproterenol stimulated myocardial adenylate cyclase. Data were obtained from the 
experiments using l-day old neonatal (V, . ,  e) or adult (A, O, 13, V) preparations. Concentration ratios (CR) were calculated by dividing 
the ratio of the EC50 for l-isoproterenol determined in the presence of alprenolol by EC50 determined in its absence. Log (CR-I) was 
plotted against alprenolol concentration. The abscissa intercepts were used to estimate the individual K i values. The individual K i (nm) 
values were:. (T) 1.19, ( .)  1.07, (e) 0.76, (V) 1.074, (©) 3.65, (A) 3.61, (13) 3.28. 
curvilinear Scatchard analysis for [BH]-DHA bind- 
ing to guinea pig heart membranes and suggested 
this was due to negative cooperativity among recep- 
tors. Winek and Bhalla (34) reported that [3H]-D- 
HA concentrations in excess of 5 nM, bound to a 
second class of low affinity sites in rat myocardium. 
Due to the uncertainty of the K d values that 
could be estimated by this approach, we sought 
verification by determining the K i of adenylate cy- 
clase with 1-alprenolol. The null hypothesis for 
these studies was based on the assumption that the 
two forms of the antagonist (DHA and [BH]-DHA) 
lack intrinsic activity and possess equal affinity for 
the receptor as claimed by Mukherjee et al. (23); 
consequently, both parameters, K d and Ki, should 
be equal. These data revealed the Kd'S to be about 
3.5-fold greater than the Ki's for WPM derived 
from either the 1-day old neonate or adult. Several 
lines of evidence favor the validity of the K i values. 
The K i obtained for the adult (3.5 nM) was close to 
that reported by Kaumann and Birnbaumer (14) for 
the inhibition of myocardial adenylate cyclase ac- 
tivity (4.2 nM) and papillary muscle contraction 
(1.7 nM) by alprenolol. In addition, the Schild 
analysis conformed better to theoretical expecta- 
tions than the Scatchard analysis. 
Discrepancies between the K d and K i of an an- 
tagonist have been noted elsewhere in the literature. 
Coleman et al. (8) measured K d and K i values for 
various derivatives of phenoxypropranolamines in 
cardiac membranes. The relative K d values as esti- 
mated from linear regression analysis of these data 
were about 3-fold greater than the Ki's for cardiac 
membranes. Lucas et al. (20) found the K d for 
alprenoloi and [3H]-DHA to be two times greater 
than the K i in C6-glioma cells. Other investigators 
employing adult cardiac membrane preparations 
comparable to those used in this study have esti- 
mated Kd'S for [3H]-DHA to range between 0.3 and 
10.8 nM (median = 6 n M)  and RD's between 
35-350 fmo1/mg protein (median = 89 fmol /mg 
protein (1, 3, 5, 6, 11, 16, 17, 18, 33, 34). The only 
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previous report on rabbit heart membranes (9) es- 
timated a [3H]-DHA K d of 6.1 nM as compared to 
13.2 nM in the present study. 
We found that Schild and Scatchard analyses 
predicted a 3.7-fold increase in the K d of the adult 
receptor when Compared to the neonate, indicating 
that Scatchard analysis accurately reflected 
changes in K d and RD occurring during develop- 
ment. In contrast to the differences in K d observed 
with alprenolol, the K d ofisoproterenol determined 
in 1-day old and adult tissues were similar. These 
observations suggested the existence of develop- 
mentally regulated distinctions between agonist 
and antagonist binding to the/3-adrenergic recep- 
tor. Other investigators using cardiac membrane 
preparations have indicated an absence Of matura- 
tionally related changes in the K d of [3H]-DHA. 
These studies employed rats (3,32), and mice (5). 
The demonstration of an increase in/3-adrenergic 
receptor density in adult as compared to neonate 
cardiac membranes is also contrary to previous 
reports. Baker and Potter  (3) and Whitsett and 
Darovec-Beckerman (32) observed a decrease in the 
RD (per g of tissue) of adult rats when compared to 
2-week old animals. Chen et al. (5) described a 
progressive 4-fold increase in RD (relative to tissue 
weight) between the 17-day old fetus and 3-day old 
neonate, which was followed by a 50% reduction in 
RD at 3-5 months of age. While species-specific 
differences may account for the lack of correlation 
between these reports and the current study, varia- 
tions in membrane preparation were also evident. 
Changes in the reactivity of/3-adrenergic effec- 
tors during development have been associated with 
numerous biological events including gl-owth of 
sympathetic nerve fibers (24, 30), hormonal influ- 
ences (12), as well as cellular proliferation and dif- 
ferentiation (7). Adrenergic innervation to the rab- 
bit heart develops primarily during extrauterine 
life. Friedman et al. (10) reported that norepineph- 
rine tissue levels reach adult values three weeks 
after parturition, with the major increase occurring 
between days 2 and 14. Roffi and Motelica-Heino 
(25) confirmed these data and noted a rapid in- 
crease in myocardial norepinephrine within 4 hours 
of birth, followed by little or no change between 4 
and 72 hours. This was presumed to result from an 
enhancement of sympathetic activity following de- 
livery. We were unable to detect any changes in 
receptor function or number during this phase of 
extrauterine development, which was marked by 
rapid increases in tissue catecholamine concentra- 
tion. Our data suggest that variations in endogen- 
ous tissue norepinephrine levels may not be a signif- 
icant modulator of RD during perinatal develop- 
ment. This contrasts with accompanying changes in 
RD observed following denervation supersensitivi- 
ty (35) and agonist-induced desensitization (15). 
It is well established that sympathetic induced 
myocardial responses are at least in part mediated 
by cAMP (22). Our results on the coupling efficien- 
cy of the AC system as estimated from the K d / ECs0 
ratio for isoproterenol indicate that while fewer 
/3-adrenergic receptors per mg protein are present 
in the neonate as compared to the adult, a smaller 
fraction need be occupied for maximal adenylate 
cyclase enzyme activation in the neonate. 
The analysis of developmentally related changes 
in the adenylate cyclase enzyme complex is difficult 
and requires a broad perspective. This study has 
Table 2. Characteristics of the/~-adrenergic receptor, transduction and catalytic subunits of the l-day old neonatal and adult rabbit heart 
adenylate cyclase complex 
Subunit Parameter Age of rabbit 




Receptor density (fmol/mg prot) 
K d of H3-dihydroalprenolol (riM) 
K d of 1-isoproterenol (nM) 
Coupling efficiency (Kd/ECS0 
for l-isoproterenol 
Gpp(NH)p preincubation (prnol/min/nag) 
Basal activity (pmol/rnin/nrn) 
NaF stimulated activity (pmol/min/rng) 
Activity after 5 hr (4 o C) 
86 ± 13 186 4- 18 
3.7 ± 0.5 13.2 4- 2.3 
340 300 
6.8 2.8 
25 ± 1.8 493 5- 64 
23 ± 0.8 18 + 0.3 
221 4- 28 451 + 31 
demonstrated that fl-adrenergic receptor density 
(RD) in the heart increases approximately two-fold 
from birth to adult life. Receptor affinity for the 
~-adrenergic agonist, isoproterenol, does not ap- 
pear to change; the coupling efficiency index of 
isoproterenol is greater in the neonate, potentially 
compensating for the decreased number of recep- 
tors present at this time (Table 2). 
Sodium fluoride activation and Gpp(NH)p pre- 
incubation studies have also revealed a major in- 
crease in the catalytic capacity of adenylate cyclase 
with advancing age (29). In light of cyclic AMP's 
biological role as a second messenger, these altera- 
tions in the adenylate cyclase enzyme may be relat- 
ed to the other ontogenic changes which occur in 
cardiac muscle physiology. 
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